usual MAL-PDT

PreclinicalSmall molecule

NNorwegian University of Science and Technology

usual MAL-PDT is one of 39 small molecule programs targeting Basal Cell Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Basal Cell CarcinomaActive, not recruiting

Basal Cell CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Basal Cell Carcinoma

#DrugCompanyPhaseTrials

Adriamycin

Adrucil

Opdivo

3 4

Voltaren

Novartis

Phase 2

1 5

Rocaltrol

Alnylam Pharmaceuticals

Phase 2

1 6

Opdualag

Bristol-Myers Squibb

Phase 2

1 7

Fabhalta

Regeneron

Phase 2

1 8

Yervoy

Bristol-Myers Squibb

Phase 2

1 9

Verteporfin PDT

Novartis

Phase 3

1 10

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Basal Cell Carcinoma1 trial

New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)

Completed·NNorwegian University of Science and Technology·N/A·NCT01482104·277 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for usual MAL-PDT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — usual MAL-PDT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for usual MAL-PDT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Norwegian University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNorwegian University of Science and Technology

usual MAL-PDT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Basal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News